Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALPG | P10696 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8423984 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL7247968 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1ALDH1A1TDP1KMT2A | |
| SCHEMBL19972267 | 0.86 | ALOX15 (0.45) | SMN1; SMN2L3MBTL1ALDH1A1KMT2AMAPT | |
| SCHEMBL4428619 | 0.83 | ALDH1A1 (0.48) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL7967955 | 0.83 | MAPT (0.56) | SMN1; SMN2L3MBTL1ALDH1A1LMNAKMT2A | |
| SCHEMBL10363351 | 0.82 | GAA (0.45) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL11440358 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL11813946 | 0.81 | KMT2A (0.54) | SMN1; SMN2ALDH1A1LMNATDP1KMT2A | |
| SCHEMBL22262828 | 0.81 | SMN1; SMN2 (0.43) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 | |
| SCHEMBL10977335 | 0.78 | SMN1; SMN2 (0.51) | SMN1; SMN2L3MBTL1ALDH1A1LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001002346-A1 | CRYSTALLINE SINGLE DIASTEREOMERS OF 2-CYANO-3-ARYLGLUTARATE ESTERS | SMITHKLINE BEECHAM PLC (GB) | 2001-01-11 | — | — | WO | claimed |
| EP-0986389-B1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040147754-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2004-07-29 | — | — | US | disclosed |
| US-6716985-B2 | ALCOHOLISM, PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-04-06 | — | — | US | disclosed |
| US-6590102-B1 | Hydrogenation of 2-cyano-3-(p-fluorophenyl)glutaric acid diethyl ester in the presence of catalysts to prepare isomer mixtures of ethyl 4-(p-fluorophenyl)-6-oxo-3-piperidine -carboxylate, used as intermediates of paroxetine | ASAHI GLASS COMPANY LTD. (JP) | 2003-07-08 | — | — | US | disclosed |
| US-6489347-B1 | NOVEL INTERMEDIATE CARBOXALDEHYDES FOR PHARMACEUTICAL PRODUCTS WITH ANTIDEPRESSANT AND ANTI-PARKINSON PROPERTIES | SMITHKLINE BEECHAM PLC (GB) | 2002-12-03 | — | — | US | disclosed |
| US-6476228-B1 | Process for producing piperidinecarbinols | ASAHI GLASS COMPANY LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| WO-2002076940-A2 | PROCESS FOR PREPARING ARYLPIPERIDINE CARBINOL INTERMEDIATES AND DERIVATIVES | PENTECH PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020133011-A1 | Novel process | SMITHKLINE BEECHAM PLC | 2002-09-19 | — | — | US | disclosed |
| US-20010053862-A1 | Process for preparing arylpiperidine carbinol intermediates and derivatives | PENTECH PHARMACEUTICALS, INC. | 2001-12-20 | — | — | US | disclosed |
| EP-0802185-B1 | Process for producing piperidinecarbinols | ASAHI GLASS CO LTD (JP) | 2001-10-17 | — | — | EP | disclosed |
| EP-0986389-A4 | NOVEL PROCESS | SMITHKLINE BEECHAM CORP (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6197960-B1 | REDUCTION OF CYANOGLUTARIC ACID; CYCLIZATION, ISOMERIZATION | ASAHI GLASS COMPANY LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0986389-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998053824-A1 | NOVEL PROCESS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-03 | — | — | WO | disclosed |
| EP-0802185-A1 | Process for producing piperidinecarbinols | ASAHI GLASS COMPANY LTD. (JP) | 1997-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010053862-A1 | Process for preparing arylpiperidine carbinol intermediates and derivatives | ADH1C, CBR1, MAL2 | SMN1; SMN2 4562/4885L3MBTL1 3761/4885ALDH1A1 76/4885 |
| US-20020133011-A1 | Novel process | HTR1A, HTR4, MAOA | SMN1; SMN2 3833/4885L3MBTL1 1130/4885ALDH1A1 900/4885 |
| US-20040147754-A1 | Novel process | HTR1A, HTR4, HTR2B | SMN1; SMN2 3926/4885L3MBTL1 1471/4885ALDH1A1 1013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.